Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids.
Fifteen consecutive patients with toxic epidermal necrolysis or the Stevens-Johnson syndrome managed without corticosteroids after transfer to the burn center (group 2) are compared to a previous consecutive group of 15 who received high doses of these drugs (group 1). Group 2 had a 66% survival, which was a significant improvement compared to the 33% survival in group 1 (p = 0.057). In group 1, mortality was associated with loss of more than 50% of the body surface area skin. In group 2, mortality was related to advanced age and associated diseases. Age, extent of skin loss, progression of skin loss after burn center admission, incidence of abnormal liver function tests, and the incidence of septic complications were not significantly different in the two groups (p greater than 0.10). The incidence of detected esophageal slough was similar in both groups. Nonsteroid (group 2) management was associated with a decreased incidence of ulceration of gastrointestinal columnar epithelium, Candida sepsis, and an increased survival after septic complications. The combined experience of these 30 patients suggests that corticosteroids are contraindicated in the burn center management of toxic epidermal necrolysis and the Stevens-Johnson syndrome.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001344:Autopsy; D002053:Burn Units / Q000379:methods*; D002177:Candidiasis / Q000188:drug therapy; D004947:Esophagus / Q000473:pathology; D006801:Humans; D007362:Intensive Care Units / Q000379:methods*; D008875:Middle Aged; D012772:Shock, Septic / Q000188:drug therapy; D012867:Skin / Q000473:pathology; D013203:Staphylococcal Infections / Q000188:drug therapy; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents